Biotechnology company Anixa Biosciences Inc (NASDAQ: ANIX) on Monday reported updated positive survival observations from its ongoing Phase 1 trial of liraltagene autoleucel (lira-cel), an investigational CAR-T therapy for recurrent ovarian cancer.

Data presented at the International Society for Cell & Gene Therapy 2026 Annual Meeting highlighted multiple patients surviving significantly beyond the expected median survival of three to four months for their disease stage. One patient survived 28 months following treatment, while others reached 18, 17 and 11 months, with several patients still alive at the time of follow-up.

The company also reported no dose-limiting toxicities across the first three dose cohorts, successful administration of all doses via intraperitoneal delivery, and no observed cases of immune effector cell-associated neurotoxicity syndrome or significant cytokine release syndrome. All significant adverse events reported to date were deemed unrelated to the therapy.

Lira-cel is a follicle-stimulating hormone receptor-targeted CAR-T therapy developed in collaboration with Moffitt Cancer Center and is being evaluated in women with recurrent ovarian cancer who have progressed after at least two prior therapies. The Phase 1 study is assessing safety, tolerability, maximum tolerated dose and early signs of clinical activity.

Anixa Biosciences is focused on oncology therapeutics and cancer vaccines developed in partnership with leading research institutions.